Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo. (Q55447773)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29983871%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

title

Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29983871%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1 reference

1 reference

Shuhei Shinoda

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29983871%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Seiji Kaino

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29983871%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Shogo Amano

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29983871%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Hirofumi Harima

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29983871%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Toshihiko Matsumoto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29983871%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Koichi Fujisawa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29983871%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Taro Takami

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29983871%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Naoki Yamamoto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29983871%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Takahiro Yamasaki

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29983871%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Isao Sakaida

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29983871%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

language of work or name

English

0 references

publication date

19 June 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29983871%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29983871%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29983871%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29983871%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

page(s)

28434-28444

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29983871%20AND%20SRC:MED&resulttype=core&format=json

Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma

5 April 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

Gemcitabine resistance in pancreatic ductal adenocarcinoma

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

Targeting cancer by binding iron: Dissecting cellular signaling pathways

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

Active hexose-correlated compound down-regulates HSP27 of pancreatic cancer cells, and helps the cytotoxic effect of gemcitabine

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

Methods of biological network inference for reverse engineering cancer chemoresistance mechanisms

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

Iron and cancer: more ore to be mined

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

The evolution of iron chelators for the treatment of iron overload disease and cancer.

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells.

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

Protein measurement with the Folin phenol reagent

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

The role of iron in cell cycle progression and the proliferation of neoplastic cells

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

Reduction of Ribonucleotides

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.

12 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine

12 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6033369

Cytotoxic and DNA-inhibitory effects of iron chelators on human leukaemic cell lines

30 November 2018

1 reference

12 December 2020

In vitro and in vivo effects of deferoxamine in neonatal acute leukemia

1 reference

12 December 2020

Mechanism of inhibition of mammalian ribonucleotide reductase by the iron chelate of 1-formylisoquinoline thiosemicarbazone. Destruction of the tyrosine free radical of the enzyme in an oxygen-requiring reaction

1 reference

12 December 2020

Deferoxamine for Advanced Hepatocellular Carcinoma

1 reference

12 December 2020

Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors

1 reference

12 December 2020

10.18632/ONCOTARGET.25421

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29983871%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29983871%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

PubMed publication ID

29983871

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29983871%20AND%20SRC:MED&resulttype=core&format=json